• Publications
  • Influence
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light‐chain amyloidosisExpand
  • 873
  • 23
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
Context AL amyloidosis responds poorly to oral chemotherapy and rarely leads to elimination of plasma cell dyscrasia. Amyloid cardiomyopathy is a particularly fatal complication of the disease.Expand
  • 544
  • 15
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen in thoseExpand
  • 219
  • 8
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
In immunoglobulin light chain (AL) amyloidosis, amyloid fibril deposits derived from immunoglobulin light chains produced by a clonal plasma cell dyscrasia accumulate in tissues and damage vitalExpand
  • 174
  • 6
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Acquired deficiency of factor X occurs in patients with systemic amyloid light-chain (AL) amyloidosis, presumably due to adsorption of factor X to amyloid fibrils. Of 368 consecutive patients withExpand
  • 157
  • 6
Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience
Amyloidosis of the gastrointestinal tract, with biopsy-proven disease, is rare. We reviewed a series of patients who presented with biopsy-proven gastrointestinal amyloidosis and report theirExpand
  • 88
  • 6
Update on treatment of light chain amyloidosis
Light chain amyloidosis is the most common type of amyloidosis as a consequence of protein misfolding of aggregates composed of amyloid fibrils. The clinical features are dependent on the organsExpand
  • 75
  • 6
Light-chain (AL) amyloidosis: diagnosis and treatment.
  • V. Sanchorawala
  • Medicine
  • Clinical journal of the American Society of…
  • 1 November 2006
Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease often is difficult to recognize because of itsExpand
  • 169
  • 5
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
This manuscript summarizes the recommendations that emerged from the first Roundtable on Clinical Research in Immunoglobulin Light-chain Amyloidosis (AL), a meeting sponsored by the AmyloidosisExpand
  • 202
  • 4
Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.
BACKGROUND Restrictive cardiomyopathy frequently complicates primary systemic amyloidosis (AL), yet only a small number of these patients develop large pleural effusions refractory to diureticExpand
  • 95
  • 4